Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype

• DOI: 10.2500/aap.2025.46.240105
• Publication Date: 2025-02-27T04:31:02Z
• Authors: Hazal Kayikci; Ebru Damadoglu; Melek Cihanbeylerden; Cise Tuccar; Gul Karakaya; Ali Fuat Kalyoncu
• Keywords: Omalizumab

Background: The data on subphenotypes and treatment responses to biologicals in late-onset asthma (LOA) is limited. This study aims compare the clinical characteristics severe patients receiving biological treatments, categorized into early-onset (EOA) LOA groups. Methods: Patients treated with omalizumab or mepolizumab for at least six months a tertiary care adult allergy clinic between December 2015 2023 were included. persistent respiratory symptoms starting age ≥40 years as LOA, while those onset <40 EOA. Changes Asthma Control Questionnaire (ACQ-6) scores, forced expiratory volume one second (FEV1) percentages, blood eosinophil counts assessed baseline 6 months. percentage change FEV1 (liters) relative was measured. Clinical remission rates evaluated completing year of treatment. Results: Among 87 patients, 38 (43.7%) had 49 (56.3%) Of these, 22 (25.3%) received 65 (74.7%) mepolizumab, mean duration 24.7 (±19.7) higher obesity tobacco consumption compared EOA (p = 0.041 p 0.024, respectively). There no significant differences groups ACQ percentage, liters 0.531, 0.219, 0.632, 0.700, Within scores did not significantly differ 0.801). At months, decreased but 0.002). Conclusion: Biological similar Omalizumab showed comparable efficacy, exception count changes patients.